Introduction
============

Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality and morbidity worldwide \[[@B1]\]. Although tobacco smoking is well recognized as the major risk factor for the disease, exposure to biomass smoke (BE) and other fuel combustion products has also been described as an additional risk factor \[[@B2],[@B3]\]. The association between BE, mainly wood smoke and COPD in different populations, particularly in developing countries where wood is used as fuel for cooking and heating, has been established \[[@B4]-[@B6]\]. The clinical profile of COPD associated with BE and its prognostic factors have been described in Mexican population \[[@B3],[@B5]\]. Women are more susceptible than men to this disease exhibiting bronchial symptoms, decreased exercise capacity, changes in quality of life, and augmented use of healthcare services and supplemental oxygen. Nevertheless, a lot of questions about its pathogenesis and molecular mechanisms associated with biomass combustion exposure remain unanswered \[[@B2],[@B3]\].

Several recent reports have suggested that a persistent, low-level, systemic inflammation plays a significant pathogenic role in COPD. Accordingly, elevated circulating levels of C-reactive protein (CRP) among other inflammatory markers \[[@B7]\], such as plasma and sputum matrix metalloproteinases (MMPs) and the tissue inhibitor of metalloproteinase-(TIMP)-1 levels have been reported, suggesting their participation in the pathogenesis of COPD secondary to TS \[[@B8]-[@B11]\].

Despite the growing evidences of BE as a risk factor for COPD, very little information on systemic inflammation and pathogenic mechanisms has been described \[[@B6],[@B7]\] and so far, there are few studies describing inflammatory molecules associated to changes in FEV~1~ in COPD due to BE.

The aim of the present study was to determine plasma concentrations of matrix metalloproteinase-(MMP)-1, MMP-7, MMP-9, MMP-9/TIMP-1, and CRP in COPD associated with BE, specifically to wood smoke. A group of non-smoking (NS) healthy women was considered as control group and data were compared with subjects having COPD associated to tobacco smoke (TS).

Materials and methods
=====================

Study population
----------------

Eighty women with a clinical and functional diagnosis of COPD associated with BE or tobacco smoke were recruited from the COPD Clinic from January to December 2013. The quantity of tobacco smoked and the degree of exposure to BE was determined by a clinical interview, using the Spanish version of a validated instrument that was modified to include additional questions directly related to fuels used for cooking and heating \[[@B12]\]. The main inclusion criterion was a history of daily wood smoke exposure for at least 200 hours/year or a history of tobacco smoking of at least \>10 pack/year. Cumulative exposure to wood smoke was expressed as hours/year, which was calculated by multiplying the number of years of cooking with wood by the average of daily hours spent cooking \[[@B5]\].

COPD diagnosis was confirmed by medical history and spirometry results, which were interpreted according to the GOLD criteria \[[@B13]\]. We excluded from the study groups those subjects who had both BE and tobacco exposure or a history of other chronic pulmonary conditions such as asthma, tuberculosis or bronchiectasis. Patients with COPD that participated in this study were clinically stable, with no history of exacerbations for at least 6 weeks prior to the study. Forty healthy non-smoking (NS) women volunteers with normal spirometry values, without a history of tobacco smoking or biomass smoke exposure, with no signs of infectious respiratory disease during the past 3 weeks and no history of asthma, allergy or other diseases were considered as the control group.

Informed consent was obtained from each subject and the protocol was approved by the local Ethic and Research Committees at the Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas (Protocol number B 25-12).

Measurements
------------

### Pulmonary function tests

All subjects were evaluated through spirometry both pre- and post-bronchodilator following the procedures recommended by the American Thoracic Society/European Respiratory Society \[[@B14]\]; accordingly, a dry rolling-seal volume spirometer (Sensormedics, Yorbalinda, CA, USA) was used, and Mexican standard reference equations were applied \[[@B15]\]. These reference equations are similar to the National Health and Nutrition Examination Survey III values for Mexican-Americans \[[@B16]\].

Diagnosis of COPD was established according to the history of tobacco smoking or wood smoke exposure and pulmonary function tests after inhalation of 400 μg of salbutamol \[[@B13]\].

Venous blood samples were collected from COPD patients and NS in 5 mL lithium heparin-coated tubes, centrifuged and plasma protein content was measured by the bincinchoninic acid protein assay (Pierce Chemical Company, Rockford, IL, USA) \[[@B17]\]. Plasma samples were stored at -70°C until analyzed.

Plasma MMPs and CRP quantification
----------------------------------

Concentrations of plasma MMP-1, MMP-7, MMP-9, MMP-9/TIMP-1 complex (duo set) and CRP were determined by commercially available ELISA kits (R&D Systems, Minneapolis, MN, USA), according to the manufacturers' instructions. The detection limits were: 0.023 ng/mL for MMP-1, 0.016 ng/mL for MMP-7, 0.36 ng/mL for MMP-9, 10.0 pg/mL for TIMP-1 and 0.02 μg/mL for C-reactive protein.

Statistical analysis
--------------------

Data were expressed as mean ± SD for at least three independent experiments. One-way analysis of variance (ANOVA) followed by Tukey's test were used to adjust multiple comparisons between groups. Associations between variables were performed using Pearson's correlation coefficient (r). The SPSS software for Windows (Chicago, IL*)* was used for statistical analyses*; p \<0.05* was considered statistically significant.

Results
=======

Patients' clinical characteristics
----------------------------------

General clinical characteristics of COPD patients with BE or tobacco smoke and control subjects are shown in Table [1](#T1){ref-type="table"}. Patients with BE were significantly older, shorter and with higher BMI than tobacco smoke subjects and healthy control women. The mean exposure to biomass was 230 ± 132 hours/year, whereas smokers had a mean cumulative tobacco consumption of 50 ± 30 pack/year. Despite women with BE showing a significantly lower SaO~2~, no differences were observed in the domains of the CRQ nor in the GOLD stages (Table [1](#T1){ref-type="table"}).

###### 

Clinical characteristics of COPD and NS healthy women (control)

                                                    **Control n = 40**   **BE n = 40**    **TS n = 40**      ***p***
  ------------------------------------------------ -------------------- ---------------- ---------------- --------------
  **Characteristics**                                                                                     
  Age (years)                                            65 ± 10           72 ± 8^§^          69 ± 9       0.01 vs Ctrl
  Height (cm)                                            158 ± 6           147 ± 7^§^        159 ± 10       0.01 vs TS
  0.02 vs TS                                                                                              
  Weight (Kg)                                            65.9 ± 9           62 ± 11         69 ± 9^§^      0.05 vs Ctrl
  BMI (Kg/m^2^)                                           27 ± 8             29 ± 5         26 ± 3^§^       0.01 vs BE
  **Exposure and physiological characteristics**                                                          
  Tobacco index (Pack/yr)                                   \-                 \-            50 ± 30             
  Biomass index (Hrs/year of exposure)                      \-             230 ± 132            \-               
  FEV1 (% predicted)                                   107.8 ± 8.7       62.1 ± 25.6^§^   49.5 ± 23.9^§^   0.01 vs Ctrl
  0.03 BE vs TS                                                                                           
  FVC (% predicted)                                      109 ± 9           78 ± 19^§^       82 ± 14^§^     0.01 vs Ctrl
  FEV1/FVC ratio                                         91 ± 9.5          53 ± 16^§^       56 ± 15^§^     0.01 vs Ctrl
  Bronchodilator response (FEV1; %)                         \-             9.54 ± 17         9.14 ± 8       0.883\*\*
  PaO~2~ (mmHg)                                             \-               53 ± 7          59 ± 10        0.056\*\*
  PaCO~2~ (mmHg)                                            \-               34 ± 4           32 ± 5        0.136\*\*
  6MWT (m)                                                  \-             274 ± 155        327 ± 142       0.075\*\*
  SaO~2~ (%)                                                \-               88 ± 5           91 ± 5        0.039\*\*
  **Chronic respiratory questionnaire**                                                                   
  Dyspnea                                                   \-              21 ± 10           17 ± 8        0.098\*\*
  Fatigue                                                   \-               19 ± 5           20 ± 5        0.711\*\*
  Master                                                    \-               37 ± 7           36 ± 9       0.570\*\*\*
  Control                                                   \-               22 ± 4           22 ± 5        0.988\*\*
  Total score                                               \-              99 ± 15          95 ± 17        0.283\*\*
  GOLD stage                                                                                                     
  I                                                         \-               8 (20)           8 (20)         0.075\*
  II                                                        \-              25 (63)          15 (38)      
  III                                                       \-               6 (15)          12 (30)      
  IV                                                        \-               1 (2.)           5 (12)      
  Exacerbation rate/yr (min-max)                            \-             1.27 (1-3)       1.38 (1-3)      0.495\*\*

Data are presented as mean ± SD unless otherwise indicated. Ctrl = Control; BE = biomass exposure; TS: tobacco smoking; BMI: biomass mass index; FEV~1~: forced expiratory volume in one second; FVC: forced vital capacity;% predicted: percentage of the predicted value. For GOLD stage figures are presented as number (%).

Statistical tests: ^§^ANOVA-Tukey test; \*X^2^ test; \*\*Student-T test; \*\*\*Welch test. All comparisons with Ctrl and TS were against BE after Bonferroni adjustments.

Pulmonary function tests
------------------------

Both FEV~1~ (% predicted) and FVC (% predicted) were significantly lower in women with COPD associated to smoking in comparison to control healthy women and with BE (Table [1](#T1){ref-type="table"}); similarly FVC values and FEV~1~/FVC ratio were lower in TS and BE than in controls (Table [1](#T1){ref-type="table"}). Finally, it is important to note that in terms of the GOLD classification, BE patients differ of TS patients because the majority (83%) of them are included within stages I and II, whereas TS patients are more homogenously distributed, although this difference was not statistically significant (Table [1](#T1){ref-type="table"}, p = 0.075). No differences in the rate of exacerbations were found.

MMPs plasma concentrations
--------------------------

Plasma concentration of MMP-1, MMP-7 (Figure [1](#F1){ref-type="fig"}), MMP-9 and the MMP-9/TIMP-1 complex (Figure [2](#F2){ref-type="fig"}) showed a significant increase both in tobacco smokers and BE groups in comparison with the NS control group; however, no significant differences were found among the COPD groups (Table [2](#T2){ref-type="table"}).

![**Plasma levels of MMP-1 and MMP-7 in COPD groups compared with NS healthy women (controls), and relationship between plasma MMP-1 and MMP-7 and FEV**~**1**~**(% predicted).** There was a significant difference between BE and TS with NS healthy subjects. No difference was found among COPD groups: **(A)** MMP-1. **(B)** MMP-1 between MMP-1 or MMP-7 and FEV~1~ (% predicted) in COPD and NS healthy women performed with the Pearson correlation coefficient (r). **(C)** MMP-1; r = 0.4904 and *p \<0.0001*. **(D)** MMP-7; r = 0.2902 and *p \<0.0013*. Results are expressed as mean ± SD; *p \<0.01*. NS (▪). TS (▲). BE (●).](1465-9921-15-74-1){#F1}

![**There were significant differences among BE and TS groups when compared with NS healthy women.** COPD groups did not show any difference: **(A)** MMP-9. **(B)** MM9-9/TIMP-1 complex. Relationship between MMP-9 and MM9-9/TIMP-1 complex with the FEV~1~ (% predicted) in COPD and NS healthy women was performed with the Pearson correlation coefficient (r). **(C)** MMP-9; r = 0.8037 *and p \<0.0001;***(D)** MMP-9/TIMP-1 complex; r = 0.2150 *and p \<0.0163*. Results are expressed as mean ± SD; *p \<0.01*. NS (▪). TS (▲). BE (●).](1465-9921-15-74-2){#F2}

###### 

Plasma concentration of MMPs, MMP-9/TIMP-1 complex and C-reactive protein

                                **Control**        **BE**            **TS**        ***p***
  ---------------------------- -------------- ----------------- ----------------- ---------
  **Molecule**                                                                    
  MMP-1 (ng/mL)                 1.62 ± 0.71     4.24 ± 2.17\*     3.86 ± 2.71\*     0.01
  MMP-7 (ng/mL)                 1.79 ± 0.26     2.63 ± 1.12\*     2.87 ± 1.26\*     0.01
  MMP-9 (ng/mL)                 4.46 ± 0.65     7.97 ± 3.53\*     9.07 ± 2.84\*     0.01
  MMP-9/TIMP-1 (pg/mL)          0.18 ± 0.17      0.25 ± 0.18      0.32 ± 0.21\*     0.05
  C-reactive protein (ng/mL)    12.34 ± 6.04   32.89 ± 21.29\*   35.49 ± 21.19\*    0.05

BE: Biomass exposure; TS: Tobacco smoking.

Data are express as means ± SD. \*ANOVA-Tukey test compared with Controls.

CRP plasma levels in COPD patients
----------------------------------

There was a significant increase in CRP plasma levels both in tobacco smokers and BE COPD patients compared with NS control subjects (Figure [3](#F3){ref-type="fig"}). Despite the scattered picture that can be observed in the obtained data, no significant difference among COPD groups was observed (Table [2](#T2){ref-type="table"}).

![**Plasma levels of the C-reactive protein (CRP) in COPD and NS healthy women, and relationship between CRP and FEV**~**1**~**(% predicted).** There were significant differences among BE and TS groups when compared with NS healthy women. COPD groups did not show difference among them: **(A)** plasma levels of CRP. **(B)** Relationship between plasma levels of CRP in COPD and NS healthy women with the FEV~1~ (% predicted) performed with the Pearson correlation coefficient (r). r = 0.4227 and *p \<0.0001*. Results are expressed as mean ± SD; *p \<0.01*. NS (▪). TS (▲). BE (●).](1465-9921-15-74-3){#F3}

FEV~1~ correlations
-------------------

An inverse correlation between MMP-1, MMP-7, MMP-9, MMP-9/TIMP-1 and CRP plasma concentrations with changes in observed FEV~1~ (% predicted) in both COPD groups when compared to control group was observed (Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}).

Discussion
==========

The main findings of this work are that: 1) metalloproteinases 1, 7, and 9, the MMP-9/TIPM-1 ratio and CRP concentrations are increased in plasma of subjects with COPD associated to BE, and: 2) an association among these increases and FEV~1~ exists.

Several studies carried out in different populations around the world have established that domestic exposure to biomass solid fuels combustion products is now considered an important risk factor for COPD, mainly in developing countries \[[@B3],[@B4],[@B6],[@B18]\]. A number of similarities including mortality among COPD associated with TS and BE have been observed \[[@B3],[@B6]\]. However, information on the possible role of candidate molecules already involved in the pathogenesis of COPD associated with tobacco exposure is scant in BE \[[@B6]\]. In the present work, we studied the possible role of some of those molecules. All study subjects selected were women because most patients with COPD secondary to domestic BE reported in Mexico are females \[[@B4],[@B5],[@B12]\].

MMPs play an important role in the turnover of almost all extracellular matrix molecules and are therefore probably involved in COPD pathogenesis \[[@B8],[@B19]\]. An increase in serum or plasma MMP-1 and MMP-7 concentration in COPD associated to tobacco smoking has already been demonstrated. Our current findings in BE occur in a similar way, suggesting that these enzymes could be involved in interstitial EM turnover \[[@B20]-[@B22]\]. MMP-9 plasma levels and activity have been extensively studied in patients with COPD secondary to tobacco smoke, demonstrating an active role of these enzymes during the inflammatory process that characterizes COPD, especially in the degradation of interstitial and basal membranes molecules of EM, such as types I and IV collagen and elastic fibers \[[@B23]-[@B25]\]. Additionally, an increase of MMP-9 has been reported in sputum, blood and lung tissue from smokers with COPD \[[@B26]-[@B30]\]. On the other hand, MMP-9 is inhibited by TIMP-1 and an imbalance in the MMP-9/TIMP-1 ratio could be involved in COPD pathogenesis. In this regard, Kang et al demonstrated a correlation among the increase in the MMP-9/TIMP-1 complex in lung tissue from smokers and the airflow obstruction observed \[[@B31]\] and Higashimoto et colleagues \[[@B20]\] found that circulating TIMP-1 concentration was significantly higher in stable COPD patients. This and our report suggest that excess amounts of TIMP-1 compared with those of MMP-9 may be related to airway narrowing. Moreover, our study showed an increase in the MMP-9/TIMP-1 complex that inversely correlated with airflow obstruction in both smokers and BE COPD patients, suggesting a role in COPD associated to BE as it occurs in tobacco smokers.

The increase of CRP plasma concentration has been observed in patients with COPD associated with tobacco exposure as well as in former smokers, suggesting that the inflammatory process persists even when the exposure to a risk factor has ceased \[[@B32]\]. Moreover, Higashimoto et colleagues examined various inflammatory markers where only serum CRP and MMP-9 levels were related to FEV~1~ decline \[[@B33]\]. CRP plasma concentration in biomass smoke-exposed women was previously studied in a group of subjects with COPD related to BE \[[@B34]\]. Although the study sample was small (11 non-smoking subjects), those data and ours suggest that these women develop a systemic inflammation similar to that observed in smokers. In this context, the association showing that the lower the FEV~1~ the higher the CRP levels, supports the possible role of CRP as a biomarker of systemic inflammation in BE. Our results also show that the history and annual rate of exacerbations did not affect the levels of the studied molecules since the frequency is similar in both groups of COPD.

Conclusions
===========

We report an increase of MMP-1, MMP-7, MMP-9, MMP-9/TIMP-1 ratio and CRP plasma concentrations and a correlation with FEV~1~ in women with COPD associated to BE that is similar to that observed in smokers with COPD. Further research is needed to clarify if these MMPs and the CRP participate in the pathogenesis of COPD in women exposed to BE.
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